DK1853619T3 - 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme - Google Patents

3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme

Info

Publication number
DK1853619T3
DK1853619T3 DK06736460.4T DK06736460T DK1853619T3 DK 1853619 T3 DK1853619 T3 DK 1853619T3 DK 06736460 T DK06736460 T DK 06736460T DK 1853619 T3 DK1853619 T3 DK 1853619T3
Authority
DK
Denmark
Prior art keywords
diene
treatment
methods
androsta
benzimidazol
Prior art date
Application number
DK06736460.4T
Other languages
English (en)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1853619T3 publication Critical patent/DK1853619T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06736460.4T 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme DK1853619T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
DK1853619T3 true DK1853619T3 (da) 2011-01-10

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06736460.4T DK1853619T3 (da) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme
DK10150763.0T DK2206719T3 (da) 2005-03-02 2006-03-02 Farmaceutisk sammensætning omfattende 3-beta-hydroxy-17-(1-h-benzimidazol-1-yl)androsta-5, 16-dien

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10150763.0T DK2206719T3 (da) 2005-03-02 2006-03-02 Farmaceutisk sammensætning omfattende 3-beta-hydroxy-17-(1-h-benzimidazol-1-yl)androsta-5, 16-dien

Country Status (22)

Country Link
US (1) US7875599B2 (da)
EP (2) EP2206719B1 (da)
JP (2) JP5130453B2 (da)
KR (1) KR101380959B1 (da)
CN (2) CN101155823A (da)
AT (1) ATE482969T1 (da)
AU (1) AU2006218711B2 (da)
BR (1) BRPI0607523A2 (da)
CA (1) CA2599953C (da)
DE (1) DE602006017175D1 (da)
DK (2) DK1853619T3 (da)
EA (1) EA019560B1 (da)
ES (2) ES2528055T3 (da)
HK (1) HK1115387A1 (da)
IL (3) IL185608A (da)
MX (1) MX2007010593A (da)
NZ (1) NZ561571A (da)
PL (2) PL1853619T3 (da)
PT (2) PT2206719E (da)
SI (2) SI1853619T1 (da)
WO (1) WO2006093993A1 (da)
ZA (1) ZA200708106B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US7875599B2 (en) 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010062506A2 (en) * 2008-10-28 2010-06-03 Lead Therapeutics, Inc. Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
US20110312916A1 (en) * 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
CA2770092A1 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
AU2010319697B2 (en) * 2009-11-13 2016-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
RU2013132766A (ru) * 2010-12-16 2015-01-27 Байомарин Фармасьютикал Инк. Ингибиторы cyp11b, cyp17 и/или cyp21
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
AU2012284053A1 (en) * 2011-07-18 2014-01-23 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
US9884067B2 (en) * 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CA2908577C (en) * 2013-04-04 2022-05-31 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
US11390645B2 (en) 2016-08-08 2022-07-19 Industriale Chimica S.R.L. Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
WO2019160890A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (da) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2005014023A1 (en) 2003-07-29 2005-02-17 Dompe' Pha.R.Ma S.P.A. Pharmaceutical combination of g-csf and plgf useful for blood stem cell
US7875599B2 (en) 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity

Also Published As

Publication number Publication date
EP1853619A1 (en) 2007-11-14
KR101380959B1 (ko) 2014-04-04
EA019560B1 (ru) 2014-04-30
WO2006093993A1 (en) 2006-09-08
IL210480A0 (en) 2011-03-31
BRPI0607523A2 (pt) 2009-09-08
EP1853619A4 (en) 2009-08-26
SI2206719T1 (sl) 2015-03-31
AU2006218711A2 (en) 2006-09-08
US7875599B2 (en) 2011-01-25
JP2008536807A (ja) 2008-09-11
EP2206719A3 (en) 2011-01-05
EP2206719B1 (en) 2014-10-22
DK2206719T3 (da) 2015-01-26
KR20070120119A (ko) 2007-12-21
PL1853619T3 (pl) 2011-03-31
ATE482969T1 (de) 2010-10-15
CN101155823A (zh) 2008-04-02
SI1853619T1 (sl) 2011-01-31
CN103349664A (zh) 2013-10-16
ES2353413T3 (es) 2011-03-01
DE602006017175D1 (de) 2010-11-11
PL2206719T3 (pl) 2015-03-31
CA2599953A1 (en) 2006-09-08
ES2528055T3 (es) 2015-02-03
EA200701872A1 (ru) 2008-06-30
IL210478A0 (en) 2011-03-31
JP2012255026A (ja) 2012-12-27
JP5613206B2 (ja) 2014-10-22
AU2006218711A1 (en) 2006-09-08
NZ561571A (en) 2009-09-25
US20080280864A1 (en) 2008-11-13
EP1853619B1 (en) 2010-09-29
PT1853619E (pt) 2011-01-03
JP5130453B2 (ja) 2013-01-30
ZA200708106B (en) 2008-12-31
IL185608A0 (en) 2008-01-06
IL210480A (en) 2015-06-30
EP2206719A2 (en) 2010-07-14
IL185608A (en) 2016-06-30
MX2007010593A (es) 2008-02-20
PT2206719E (pt) 2015-02-05
CA2599953C (en) 2013-08-13
AU2006218711B2 (en) 2010-11-11
HK1115387A1 (da) 2008-11-28

Similar Documents

Publication Publication Date Title
DK1853619T3 (da) 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
MX2009003876A (es) Uso de compuestos de espiro-oxindol como agentes terapeuticos.
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
SE0400346D0 (sv) Steroids for cancer treatment
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2007056500A3 (en) Compounds with activity at estrogen receptors
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
CY1116024T1 (el) 3-βητα-υδροξυ-17-(1η-βενζιμιδαζολ-1-υλ)ανδροστα-5,16-διενιο προς χρηση στη θεραπευτικη αγωγη ενος νοσηματος του προστατη
DE602004018844D1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate
TW200504044A (en) Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds
TW200740442A (en) Therapeutic agent for hypertension
AU2004907196A0 (en) Use of Naltrexone for Treating Alzheimer's Disease
GB0519270D0 (en) Chronotherapeutic delivery system for treatment of glaucoma
UA11008U (uk) Спосіб відкритої ринопластики з використанням м'язово-апоневротичного клаптя